On Demand 2023 Friday PM General Sessions

This course includes the following sessions:

  • Respiratory Conditions We Need More Help With
  • Empowering Adolescents and Young Adults for Lifelong Health
  • Complex Non-IgE Food Allergy and Extreme Food-related Anxiety
  • ProCon - Are Therapeutic Options Up to Snuff?

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 6.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Formulate a diagnostic algorithm for patients presenting with chronic cough and discuss treatment options.
  • Compare currently available therapies for the management of T2-low asthma.
  • Develop a differential diagnosis for autoimmune lung conditions and a treatment plan based on the diagnosis.
  • Relate with patient’s life/health transitions and design care paths.
  • Assess service requirements as they relate to patient’s interest in joining the military.
  • Develop guidance for young adults entering college.
  • Prepare patients for transition to adult care.
  • Contemplate the future treatment of NSAID exacerbated respiratory disease.
  • Assess the need for antibiotics in patients with chronic rhinosinusitis.
  • Identify the clinical presentations concerning an immune mediated insulin reaction and be able to choose treatment strategies to specifically target either insulin-induced urticaria
    or autoimmune panniculitis.
  • Identify and manage complex FPIES.
  • Discuss how to identify and manage complex EGID.
  • Provide practical tips on effective management of food-related anxiety.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 6.25 AMA PRA Category 1 Credit™
  • 6.25 Attendance
  • 6.25 CBRN
Course opens: 
12/01/2023
Course expires: 
11/30/2026
Part of: 
On Demand ACAAI 2023 Annual Scientific Meeting General Sessions
Rating: 
0

Deepa Patadia, MD
Ruchi Shah, MD, FACAAI
William C. Anderson, III, MD, FACAAI 
Karla Adams, MD, FACAAI 
Ruchi Gupta, MD, MPH
Mary Beth Fasano, MD, MSPH, FACAAI
Sandra M. Gawchik, DO, FACAAI
Amar Dixit, MD, FACAAI
Mandel R. Sher, MD, FACAAI
Mario Castro, MD, MPH, FACAAI
Julio Lanfranco, MD, MPH
Sami L. Bahna, MD, DrPH, Honorary Fellow
Adam Fox, MD, FRCPCH
Irene Yuan, MD
Anna H. Nowak-Wegrzyn, MD, PhD, FACAAI
Seema S. Aceves, MD, PhD
Jennifer LeBovidge, PhD
Sarah W. Spriet, DO, FACAAI
Whitney Stevens, MD, PhD, FACAAI
Andrew A. White, MD, FACAAI
Anju T. Peters, MD
Larry Borish, MD, FACAAI

Available Credit

  • 6.25 AMA PRA Category 1 Credit™
  • 6.25 Attendance
  • 6.25 CBRN
Please login or create an account to take this course.